New drug cocktail shows promise for tough stomach cancer
NCT ID NCT03223376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding fruquintinib to standard chemotherapy (paclitaxel) helps people with advanced stomach cancer live longer. It included 703 patients whose cancer had worsened after initial treatment. The goal was to see if the combination improves survival and slows cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huchison Medi Pharma Investigational site
Nanjing, Jiangsu, 210000, China
-
Hutchison Medi Pharma Invesigational sites
Hefei, Anhui, 230000, China
-
Hutchison Medi Pharma Investigational Site
Guangzhou, Guangdong, 510030, China
-
Hutchison Medi Pharma Investigational site
Harbin, Heilongjiang, 150081, China
-
Hutchison Medi Pharma Investigational site
Shanghai, 200125, China
-
Hutchison Medi Pharma Investigational sites
Hangzhou, Zhejiang, 310000, China
-
Hutchison Medi Pharma Investigational sites
Beijing, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- Acupuncture with a jolt: could needles shield nerves from chemo?
- Real-World check: does adding nivolumab to chemo help stomach cancer patients?
- Fasting during immunotherapy: a new way to boost treatment?
- New drug combo shows promise for tough stomach cancers